CMAB Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 250

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $24.4M

CMAB General Information

Description

Developer of cell line development research, aseptic drugs and GMP manufacturing. The company provides various antibodies and biologics such as aseptic drugs and GMP (guanosine monophosphate) for clients in China and across the globe through, enabling its clients to receive various pre-clinical and early-stage clinical products from them.

Contact Information

Website
www.cmabbio.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Building C37
  • No. 188 Dongping Street, Suzhou Industrial Park
  • Suzhou, Jiangsu 215123
  • China
+86 0512
Primary Industry
Other Pharmaceuticals and Biotechnology
Acquirer
Corporate Office
  • Building C37
  • No. 188 Dongping Street, Suzhou Industrial Park
  • Suzhou, Jiangsu 215123
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CMAB Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 07-May-2021 $24.4M Completed Generating Revenue
3. Early Stage VC (Series B1) 02-Feb-2019 Completed Generating Revenue
2. Early Stage VC (Series B) 02-Apr-2018 $34M $72M Completed Generating Revenue
1. Early Stage VC (Series A) 02-Jan-2018 $38M $38M Completed Generating Revenue
To view CMAB’s complete valuation and funding history, request access »

CMAB Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell line development research, aseptic drugs and GMP manufacturing. The company provides various antibodie
Other Pharmaceuticals and Biotechnology
Suzhou, China
250 As of 2021

Kaiseraugst, Switzerland
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CMAB Competitors (2)

One of CMAB’s 2 competitors is Solvias, a Private Equity-Backed company based in Kaiseraugst, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Solvias Private Equity-Backed Kaiseraugst, Switzerland
Celonic Corporate Backed or Acquired Basel, Switzerland
You’re viewing 2 of 2 competitors. Get the full list »

CMAB Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CMAB Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
CBC Group (Singapore) PE/Buyout Minority
CDBI Partners Venture Capital Minority
Cormorant Asset Management PE/Buyout Minority
Hangzhou Tigermed Consulting Company Corporation Minority
I-Bridge Capital Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

CMAB FAQs

  • When was CMAB founded?

    CMAB was founded in 2017.

  • Where is CMAB headquartered?

    CMAB is headquartered in Suzhou, China.

  • What is the size of CMAB?

    CMAB has 250 total employees.

  • What industry is CMAB in?

    CMAB’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is CMAB a private or public company?

    CMAB is a Private company.

  • What is the current valuation of CMAB?

    The current valuation of CMAB is .

  • What is CMAB’s current revenue?

    The current revenue for CMAB is .

  • How much funding has CMAB raised over time?

    CMAB has raised $72M.

  • Who are CMAB’s investors?

    CBC Group (Singapore), CDBI Partners, Cormorant Asset Management, Hangzhou Tigermed Consulting Company, and I-Bridge Capital are 5 of 8 investors who have invested in CMAB.

  • Who are CMAB’s competitors?

    Solvias and Celonic are competitors of CMAB.

  • When was CMAB acquired?

    CMAB was acquired on 07-May-2021.

  • Who acquired CMAB?

    CMAB was acquired by WuXi Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process